NEW YORK health magazine 3d: The US Food and Drug Authority approved the drug for the first three-D printed using an ink jet printer that is built to go as quickly dissolves in the body.
The company made its name aspiritom drug that is now available to patients in the United States. The three-CD release of pharmaceutical and medical research aspiritom printer but the ink jet printer is made from the powder that dissolves quickly in the body go on. Some medicines can be difficult for patients but also dangerous, especially when the patient is very old, but his shot from very easy to doctor.
Work is currently underway to patients from alternative sources and the company would have only half the amount of $ 3 million is allocated to research in the disease of chickens and a shaking of the drug. aspiritom a medicine for epilepsy that may be taken to a whole new way.
According to experts, three-D is a big advantage apparently prepared medicinal printer look that the patient eat and dress in the latest styles at low doses of your medicine, even tenth and twentieth of a tablet medication can ditch the mark.
The company made its name aspiritom drug that is now available to patients in the United States. The three-CD release of pharmaceutical and medical research aspiritom printer but the ink jet printer is made from the powder that dissolves quickly in the body go on. Some medicines can be difficult for patients but also dangerous, especially when the patient is very old, but his shot from very easy to doctor.
Work is currently underway to patients from alternative sources and the company would have only half the amount of $ 3 million is allocated to research in the disease of chickens and a shaking of the drug. aspiritom a medicine for epilepsy that may be taken to a whole new way.
According to experts, three-D is a big advantage apparently prepared medicinal printer look that the patient eat and dress in the latest styles at low doses of your medicine, even tenth and twentieth of a tablet medication can ditch the mark.
No comments:
Post a Comment